Traws defers midphase flu study after negative regulatory review
U.K. regulators have issued a “negative review” of Traws Pharma’s planned human influenza challenge study, forcing the biotech to defer a phase 2a trial tied to...
U.K. regulators have issued a “negative review” of Traws Pharma’s planned human influenza challenge study, forcing the biotech to defer a phase 2a trial tied to $20 million in funding.